ZP 4982

Drug Profile

ZP 4982

Alternative Names: ZP4982

Latest Information Update: 14 Jun 2016

Price : $50

At a glance

  • Originator Zealand Pharma
  • Class Antihyperglycaemics; Peptides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 12 Jun 2016 Pharmacodynamics data from a preclinical study in Diabetes mellitus presented at the 76th Annual Scientific Sessions of the American Diabetes Association (ADA-2016)
  • 08 Jun 2016 Preclinical trials in Diabetes mellitus in Denmark (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top